Eli Lilly (LLY +2.6%) pops after a new study shows its experimental Alzheimer’s treatment slowed...

|About: Eli Lilly and Company (LLY)|By:, SA News Editor

Eli Lilly (LLY +2.6%) pops after a new study shows its experimental Alzheimer’s treatment slowed memory loss and cognitive decline in early-stage patients by ~30%, offering the first evidence that a medication may hamper the course of the ailment. The independent study supports LLY’s August report that showed the drug, solanezumab, slowed mental decline in those with mild Alzheimer’s.